SLDB250117P12500
- 0.00
- 0.000.00%
Solid Biosciences Newsroom
Solid Biosciences Added to the Nasdaq Biotechnology Index
William Blair Maintains Solid Biosciences(SLDB.US) With Buy Rating
Solid Biosciences Receives Buy Rating Amid Promising Developments and Accelerated Approval Prospects for SGT-003
SOLiD Awarded NTIA Grant for Open RAN Development Project
PepGen Stock Craters 35% on FDA Clinical Hold
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst
Wedbush Initiates Solid Biosciences(SLDB.US) With Buy Rating, Announces Target Price $16
H.C. Wainwright Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $16
HC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $16 Price Target
Solid Biosciences Initiated at Market Outperform by JMP Securities
JMP Securities Initiates Solid Biosciences(SLDB.US) With Buy Rating, Announces Target Price $15
Buy Rating Affirmed: Solid Biosciences' Strong Potential in Gene Therapy for DMD Highlighted by Innovative Technologies and Attractive Valuation
Analysts Conflicted on These Healthcare Names: Solid Biosciences (SLDB), Foghorn Therapeutics (FHTX) and KalVista Pharmaceuticals (KALV)
Solid Biosciences Collaborating With Mayo Clinic to Develop Cardiac Gene Therapies
Express News | Solid Biosciences Announces Collaboration With Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies
Express News | Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Reports Increased Losses Amid R&D Focus
Solid Biosciences to Present at the Jefferies London Healthcare Conference
Express News | jpmorgan lowered the target stock price of solid biosciences from $15.00 to $12.00 per share.